


# PRODUCT INFORMATION



## JWH 250 N-(4-hydroxypentyl) metabolite-d<sub>5</sub> Item No. 11749

**CAS Registry No.:** 1782062-60-5  
**Formal Name:** 1-(1-(4-hydroxypentyl)-1H-indol-3-yl)-2,4,5,6,7-d<sub>5</sub>-2-(2-methoxyphenyl)ethanone  
**MF:** C<sub>22</sub>H<sub>20</sub>D<sub>5</sub>NO<sub>3</sub>  
**FW:** 356.5  
**Chemical Purity:** ≥98% (JWH 250 N-(4-hydroxypentyl) metabolite)  
**Deuterium Incorporation:** ≥99% deuterated forms (d<sub>1</sub>-d<sub>5</sub>); ≤1% d<sub>0</sub>  
**UV/Vis.:** λ<sub>max</sub>: 212, 246, 304 nm  
**Supplied as:** A solution in methanol  
**Storage:** -20°C  
**Stability:** ≥5 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Description

JWH 250 N-(4-hydroxypentyl) metabolite-d<sub>5</sub> (Item No. 11749) is intended for use as an internal standard for the quantification of JWH 250 N-(4-hydroxypentyl) metabolite (Item No. 10939) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

JWH 250 is a synthetic cannabinoid (CB) which potently activates both CB<sub>1</sub> and CB<sub>2</sub> receptors (K<sub>i</sub> = 11 and 33 nM, respectively).<sup>1</sup> It has been identified in herbal blends.<sup>2</sup> JWH 250 N-(4-hydroxypentyl) metabolite (Item No. 10939) is expected to be a cytochrome P450 phase I metabolite of JWH 250, detectable both in serum and urine.<sup>3-5</sup>

### References

- Huffman, J.W., Szklennik, P.V., Almond, A., *et al.* 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. *Bioorg. Med. Chem. Lett.* **15(18)**, 4110-4113 (2005).
- Kikura-Hanajiri, R., Uchiyama, N., and Goda, Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. *Leg. Med. (Tokyo)* **13(3)**, 109-115 (2011).
- Wintermeyer, A., Möller, I., Thevis, M., *et al.* In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. *Anal. Bioanal. Chem.* **398(5)**, 2141-2153 (2010).
- Zhang, Q., Ma, P., Cole, R.B., *et al.* Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB<sub>2</sub>) by HPLC-MS/MS. *Anal. Bioanal. Chem.* **386(5)**, 1345-1355 (2006).
- Sobolevsky, T., Prasolov, I., and Rodchenkov, G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. *Forensic Sci. Int.* **200(1-3)**, 141-147 (2010).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/15/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM